{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:55:14Z","timestamp":1769086514435,"version":"3.49.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>During the first wave of the coronavirus-disease 2019 (covid-19) pandemic in early 2020, hydroxychloroquine (HCQ) was widely prescribed in light of in vitro activity against severe acute respiratory syndrome\u2013coronavirus-2 (SARS-CoV-2). Our objective was to evaluate in early 2020 the rate of French hospitalists declaring having prescribed HCQ to treat covid-19 patients outside any therapeutic trial, compare the reasons and the determinants for having prescribed HCQ or not.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Material and methods<\/jats:title>\n<jats:p>A national inquiry submitted by email from May 7 to 25, 2020, to a sample of French hospitalists: doctors managing patients hospitalized for covid-19 in a French department of internal medicine or infectious diseases and identified in the directories of French hospitals or as a member of the French Infectious Diseases Society (SPILF). Primary outcome was the percentage of hospitalists declaring having prescribed HCQ to covid-19 patients. Secondary outcomes were reasons and determinants of HCQ prescription.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among 400 (22.8%) responding hospitalists, 45.3% (95% CI, 40.4 to 50.1%) declared having prescribed HCQ to covid-19 patients. Two main profiles were discerned: HCQ prescribers who did not raise its efficacy as a motive, and non-prescribers who based their decision on evidence-based medicine. Multivariate analysis retained the following prescription determinants (adjusted odds ratio; 95% confidence interval): a departmental procedure for HCQ prescription (8.25; 4.79 to 14.20), having prescribed other treatments outside a therapeutic trial (3.21; 1.81 to 5.71), prior HCQ prescription (2.75; 1.5 to 5.03) and HCQ prescribed within the framework of a therapeutic trial (0.56; 0.33 to 0.95).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Almost half of the hospitalists prescribed HCQ. The physician\u2019s personality (questioning or not evidence-based\u2013medicine principles in the context of the pandemic) and departmental therapeutic procedures were the main factors influencing HCQ prescription. Establishment of \u201ctherapeutic\u201d procedures represents a potential means to improve the quality of therapeutic decision-making during a pandemic.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0261843","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T19:10:37Z","timestamp":1642792237000},"page":"e0261843","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7282-6512","authenticated-orcid":true,"given":"Antoine","family":"Bosquet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Comlan","family":"Affo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Plaisance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Poenou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"pone.0261843.ref001","unstructured":"WHO Coronavirus (COVID-19) Dashboard. [cited 11 Mar 2021]. Available: https:\/\/covid19.who.int."},{"key":"pone.0261843.ref002","doi-asserted-by":"crossref","first-page":"E405","DOI":"10.1503\/cmaj.200438","article-title":"Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic","volume":"192","author":"MP Cheng","year":"2020","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can"},{"key":"pone.0261843.ref003","first-page":"m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"R Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"pone.0261843.ref004","doi-asserted-by":"crossref","first-page":"287","DOI":"10.7326\/M20-2496","article-title":"Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19","volume":"173","author":"AV Hernandez","year":"2020","journal-title":"Ann Intern Med"},{"key":"pone.0261843.ref005","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19","volume":"49","author":"J Chen","year":"2020","journal-title":"Zhejiang Xue Xue Bao Yi Xue Ban J Zhejiang Univ Med Sci"},{"key":"pone.0261843.ref006","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s11427-020-1732-2","article-title":"Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19","volume":"63","author":"B Yu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"pone.0261843.ref007","first-page":"61","article-title":"Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19","volume":"11","author":"A. Belayneh","year":"2020","journal-title":"Treatment in Africa Against WHO Recommendation. Res Rep Trop Med"},{"key":"pone.0261843.ref008","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/M20-1223","article-title":"A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19","volume":"172","author":"AHJ Kim","year":"2020","journal-title":"Ann Intern Med"},{"key":"pone.0261843.ref009","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/jamainternmed.2020.1764","article-title":"Internet Searches for Unproven COVID-19","volume":"180","author":"M Liu","year":"2020","journal-title":"Therapies in the United States. JAMA Intern Med"},{"key":"pone.0261843.ref010","unstructured":"Breaking Results: Sermo\u2019s COVID-19 Real Time Global Barometer. In: app.sermo.com\/covid19-barometer [Internet]. [cited 11 Mar 2021]. Available: https:\/\/app.sermo.com\/covid19-barometer."},{"key":"pone.0261843.ref011","unstructured":"Impact de la crise du Covid sur l\u2019\u00e9thique m\u00e9dicale: r\u00e9sultats d\u2019enqu\u00eate. In: Medscape [Internet]. [cited 11 Mar 2021]. Available: https:\/\/francais.medscape.com\/diaporama\/33000220."},{"key":"pone.0261843.ref012","first-page":"667","article-title":"Inpatient Care during the COVID-19 Pandemic: A Survey of Italian Physicians","volume":"99","author":"M Attanasi","year":"2020","journal-title":"Respir Int Rev Thorac Dis"},{"key":"pone.0261843.ref013","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.2020.9184","article-title":"Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States","volume":"323","author":"M Vaduganathan","year":"2020","journal-title":"JAMA"},{"key":"pone.0261843.ref014","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1001\/jamainternmed.2020.2594","article-title":"US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020","volume":"180","author":"N Shehab","year":"2020","journal-title":"JAMA Intern Med"},{"key":"pone.0261843.ref015","unstructured":"Usage des m\u00e9dicaments de ville en France durant l\u2019\u00e9pid\u00e9mie de Covid-19: point de situation \u00e0 la fin du confinement\u2014Point d\u2019Information\u2014ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. [cited 11 Mar 2021]. Available: https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Usage-des-medicaments-de-ville-en-France-durant-l-epidemie-de-Covid-19-point-de-situation-a-la-fin-du-confinement-Point-d-Information."},{"key":"pone.0261843.ref016","unstructured":"D\u00e9cret n\u00b0 2020\u2013314 du 25 mars 2020 compl\u00e9tant le d\u00e9cret n\u00b0 2020\u2013293 du 23 mars 2020 prescrivant les mesures g\u00e9n\u00e9rales n\u00e9cessaires pour faire face \u00e0 l\u2019\u00e9pid\u00e9mie de covid-19 dans le cadre de l\u2019\u00e9tat d\u2019urgence sanitaire\u2014L\u00e9gifrance. [cited 11 Mar 2021]. Available: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000041755775\/."},{"key":"pone.0261843.ref017","unstructured":"Annuaire hospitalier et m\u00e9dico-social FHF\u2013F\u00e9d\u00e9ration Hospitali\u00e8re de France (FHF). [cited 11 Mar 2021]. Available: https:\/\/etablissements.fhf.fr\/annuaire\/."},{"key":"pone.0261843.ref018","unstructured":"32 CHRU\u2014R\u00e9seau CHU, l\u2019actualit\u00e9 des CHU. [cited 11 Mar 2021]. Available: https:\/\/www.reseau-chu.org\/32-chru\/."},{"key":"pone.0261843.ref019","first-page":"224","article-title":"Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists","volume":"26","author":"B Mehta","year":"2020","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"pone.0261843.ref020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cmi.2020.08.022","article-title":"Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis","volume":"27","author":"T Fiolet","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"pone.0261843.ref021","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials","volume":"12","author":"C Axfors","year":"2021","journal-title":"Nat Commun"},{"key":"pone.0261843.ref022","unstructured":"COVID-19\u2014Dispositif renforc\u00e9 de Pharmacovigilance et d\u2019Addictovigilance\u2014ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. [cited 11 Mar 2021]. Available: https:\/\/www.ansm.sante.fr\/Declarer-un-effet-indesirable\/Systemes-de-vigilances-de-l-Agence\/COVID-19-Dispositif-renforce-de-Pharmacovigilance-et-d-Addictovigilance\/(offset)\/0https:\/\/www.ansm.sante.fr\/content\/download\/183671\/2402443\/version\/1\/file\/20200930_Rapport-Enquete-COVID-n15.pdf."},{"key":"pone.0261843.ref023","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/acr2.11148","article-title":"Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic","volume":"2","author":"K Michaud","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"pone.0261843.ref024","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41586-020-01165-3","article-title":"Chloroquine hype is derailing the search for coronavirus treatments","volume":"580","author":"H. Ledford","year":"2020","journal-title":"Nature"},{"key":"pone.0261843.ref025","unstructured":"Is France\u2019s president fueling the hype over an unproven coronavirus treatment? | Science | AAAS. [cited 29 Apr 2021]. Available: https:\/\/www.sciencemag.org\/news\/2020\/04\/france-s-president-fueling-hype-over-unproven-coronavirus-treatment."},{"key":"pone.0261843.ref026","unstructured":"WHO | Managing Ethical Issues in Infectious Disease Outbreaks. In: WHO [Internet]. World Health Organization; [cited 8 Mar 2021]. Available: http:\/\/www.who.int\/ethics\/publications\/infectious-disease-outbreaks\/en\/."},{"key":"pone.0261843.ref027","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","article-title":"Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates","volume":"585","author":"P Maisonnasse","year":"2020","journal-title":"Nature"},{"key":"pone.0261843.ref028","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.3390\/v10050268","article-title":"Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection","volume":"10","author":"P Roques","year":"2018","journal-title":"Viruses"},{"key":"pone.0261843.ref029","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/jama.2020.4742","article-title":"Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics","volume":"323","author":"AC Kalil","year":"2020","journal-title":"JAMA"},{"key":"pone.0261843.ref030","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","author":"TRC Group","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0261843.ref031","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1345\/aph.1D390","article-title":"Factors that influence prescribing decisions","volume":"38","author":"GT Schumock","year":"2004","journal-title":"Ann Pharmacother"},{"key":"pone.0261843.ref032","first-page":"795","article-title":"Factors Influencing Prescribing Decisions of Physicians: A Review.","volume":"28","author":"M Davari","year":"2018","journal-title":"Ethiop J Health Sci"},{"key":"pone.0261843.ref033","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/medethics-2020-106306","article-title":"Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making","volume":"46","author":"YSJ Aquino","year":"2020","journal-title":"J Med Ethics"},{"key":"pone.0261843.ref034","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1001\/jama.2020.4984","article-title":"Optimizing the Trade-off Between Learning and Doing in a Pandemic","volume":"323","author":"DC Angus","year":"2020","journal-title":"JAMA"},{"key":"pone.0261843.ref035","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.15585\/mmwr.mm6935a4","article-title":"Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment\u2014United States, January-June 2020","volume":"69","author":"L Bull-Otterson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0261843.ref036","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/jep.13484","article-title":"Hydroxychloroquine for prophylaxis of COVID-19 physicians survey: Despite lack of evidence, many would take or give to dear ones, and despite the perceived necessity of an RCT, few would participate","volume":"26","author":"C Baicus","year":"2020","journal-title":"J Eval Clin Pract"},{"key":"pone.0261843.ref037","first-page":"CD003543","article-title":"Interventions to improve antibiotic prescribing practices for hospital inpatients.","volume":"2","author":"P Davey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0261843.ref038","first-page":"2018","article-title":"Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism","author":"SR Kahn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0261843.ref039","doi-asserted-by":"crossref","first-page":"m1936","DOI":"10.1136\/bmj.m1936","article-title":"Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review","volume":"369","author":"A Dagens","year":"2020","journal-title":"BMJ"},{"key":"pone.0261843.ref040","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1126\/science.185.4157.1124","article-title":"Judgment under Uncertainty: Heuristics and Biases","volume":"185","author":"A Tversky","year":"1974","journal-title":"Science"},{"key":"pone.0261843.ref041","first-page":"2826","article-title":"Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and","volume":"35","author":"JJ Harrigan","year":"2020","journal-title":"Outpatient Prescribing. J Gen Intern Med"},{"key":"pone.0261843.ref042","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/1744666X.2020.1792778","article-title":"Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19","volume":"16","author":"SE Sattui","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"pone.0261843.ref043","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19","volume":"383","author":"RECOVERY Collaborative Group","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0261843.ref044","unstructured":"HCSP. SARS-CoV-2: therapeutic recommendations. Rapp HCSP. Paris: Haut Conseil de la Sant\u00e9 Publique; 2020 Mar. Available: https:\/\/www.hcsp.fr\/Explore.cgi\/avisrapportsdomaine?clefr=801."},{"key":"pone.0261843.ref045","unstructured":"Organization WH. Clinical management of COVID-19: interim guidance, 27 May 2020. 2020 [cited 11 Mar 2021]. Available: https:\/\/apps.who.int\/iris\/handle\/10665\/332196."},{"key":"pone.0261843.ref046","first-page":"710","article-title":"[COVID-19: treatment strategies of German-speaking pediatric rheumatologists: Results of an online survey].","volume":"79","author":"A Janda","year":"2020","journal-title":"Z Rheumatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T19:11:24Z","timestamp":1642792284000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261843"}},"subtitle":[],"editor":[{"given":"Abdelwahab","family":"Omri","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261843","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}